Zhang Lu-Qiang, Yang Hao, Liu Jun-Jie, Zhang Li-Rong, Hao Yu-Duo, Guo Jun-Mei, Lin Hao
Laboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China.
Department of Radiation Oncology, Inner Mongolia Cancer Hospital and Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot 010020, China.
Comput Struct Biotechnol J. 2022 Oct 7;20:5535-5546. doi: 10.1016/j.csbj.2022.10.004. eCollection 2022.
Lung adenocarcinoma is a malignancy with a low overall survival and a poor prognosis. Studies have shown that lung adenocarcinoma progression relates to locus-specific/global changes in histone modifications. To explore the relationship between histone modification and gene expression changes, we focused on 11 histone modifications and quantitatively analyzed their influences on gene expression. We found that, among the studied histone modifications, H3K79me2 displayed the greatest impact on gene expression regulation. Based on the Shannon entropy, 867 genes with differential H3K79me2 levels during tumorigenesis were identified. Enrichment analyses showed that these genes were involved in 16 common cancer pathways and 11 tumors and were target-regulated by -regulatory elements, such as Tp53 and WT1. Then, an open-source computational framework was presented (https://github.com/zlq-imu/Identification-of-potential-LUND-driver-genes). Twelve potential driver genes were extracted from the genes with differential H3K79me2 levels during tumorigenesis. The expression levels of these potential driver genes were significantly increased/decreased in tumor cells, as assayed by RT-qPCR. A risk score model comprising these driver genes was further constructed, and this model was strongly negatively associated with the overall survival of patients in different datasets. The proportional hazards assumption and outlier test indicated that this model could robustly distinguish patients with different survival rates. Immune analyses and responses to immunotherapeutic and chemotherapeutic agents showed that patients in the high and low-risk groups may have distinct tendencies for clinical selection. Finally, the regions with clear H3K79me2 signal changes on these driver genes were accurately identified. Our research may offer potential molecular biomarkers for lung adenocarcinoma treatment.
肺腺癌是一种总体生存率低且预后不良的恶性肿瘤。研究表明,肺腺癌的进展与组蛋白修饰的位点特异性/全局变化有关。为了探究组蛋白修饰与基因表达变化之间的关系,我们聚焦于11种组蛋白修饰,并定量分析了它们对基因表达的影响。我们发现,在所研究的组蛋白修饰中,H3K79me2对基因表达调控的影响最大。基于香农熵,鉴定出867个在肿瘤发生过程中H3K79me2水平存在差异的基因。富集分析表明,这些基因参与了16条常见的癌症通路和11种肿瘤,并且受Tp53和WT1等调控元件的靶向调控。然后,我们提出了一个开源计算框架(https://github.com/zlq-imu/Identification-of-potential-LUND-driver-genes)。从肿瘤发生过程中H3K79me2水平存在差异的基因中提取了12个潜在的驱动基因。通过RT-qPCR检测发现,这些潜在驱动基因在肿瘤细胞中的表达水平显著升高/降低。进一步构建了一个包含这些驱动基因的风险评分模型,该模型与不同数据集中患者的总体生存率呈强烈负相关。比例风险假设和异常值检验表明,该模型能够可靠地区分不同生存率的患者。免疫分析以及对免疫治疗和化疗药物的反应表明,高风险组和低风险组的患者在临床选择上可能有不同的倾向。最后,准确鉴定出了这些驱动基因上H3K79me2信号变化明显的区域。我们的研究可能为肺腺癌治疗提供潜在的分子生物标志物。